In conclusion, our real-world study demonstrates that frail patients with advanced NSCLC and poor PS often receive less intensive treatment, even when their PD-L1 status predicts suboptimal response to ICI monotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.